Our 2014 Year in Review provides an overview of the oncology therapies approved over the last twelve months and current trends in drug development. This Report also features two of Biologics’ Oncology Board of Advisors, who provide insight on two emerging therapies.
2014 approvals include immunotherapies & first oral for ovarian cancer
With eight new approvals and one newly approved indication, 2014 was an exciting year in oncology research and development. Merck’s Keytruda (pembrolizumab), the first in a new class of immunotherapies called PD-1 inhibitors, received approval along with first-in-class PARP-inhibitor Lynparza (olaparib), approved for BRCA mutated ovarian cancer. First-in-class drugs are those drugs that use new or unique mechanisms of action for treating specific conditions.
Immunotherapies are designed to use the body’s own immune system to fight tumors. Keytruda (pembrolizumab) was approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. PD-1 inhibitors use a protein called programmed death receptor 1 to allow the body’s immune system to fight cancer cells. Keytruda is given intravenously.